We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study.
- Authors
Millán Núñez-Cortés, Jesús; Cases Amenós, Aleix; Ascaso Gimilio, Juan Francisco; Barrios Alonso, Vivencio; Pascual Fuster, Vicente; Pedro-Botet Montoya, Juan Carles; Pintó Sala, Xavier; Serrano Cumplido, Adalberto
- Abstract
Introduction and Objectives: Despite the recognized clinical benefit of statins on cardiovascular prevention, providing correct management of hypercholesterolaemia, possible adverse effects of their use cannot be disregarded. Previously published data shows that there is a risk of developing diabetes mellitus or experiencing changes in glucose metabolism in statin-treated patients. The possible determining factors are the drug characteristics (potency, dose), patient characteristics (kidney function, age, cardiovascular risk and polypharmacy because of multiple disorders) and the pre-diabetic state. Methods: In order to ascertain the opinion of the experts (primary care physicians and other specialists with experience in the management of this type of patient) we conducted a Delphi study to evaluate the consensus rate on diverse aspects related to the diabetogenicity of different statins, and the factors that influence their choice. Results: Consensus was highly significant concerning aspects such as the varying diabetogenicity profiles of different statins, as some of them do not significantly worsen glucose metabolism. There was an almost unanimous consensus that pitavastatin is the safest statin in this regard. Conclusions: Factors to consider in the choice of a statin regarding its diabetogenicity are the dose and patient-related factors: age, cardiovascular risk, diabetes risk and baseline metabolic parameters (which must be monitored during the treatment), as well as kidney function.
- Subjects
CARDIOVASCULAR disease diagnosis; PREVENTION of heart diseases; HYPERCHOLESTEREMIA treatment; TYPE 2 diabetes risk factors; STATINS (Cardiovascular agents); PREDIABETIC state; BLOOD sugar; CARBOHYDRATE metabolism; CHI-squared test; DELPHI method; PEOPLE with diabetes; CLINICAL drug trials; FISHER exact test; GLUCOSE; QUINOLINE; RESEARCH funding; DISEASE management; DATA analysis; DATA analysis software; DIAGNOSIS
- Publication
American Journal of Cardiovascular Drugs, 2017, Vol 17, Issue 2, p135
- ISSN
1175-3277
- Publication type
Article
- DOI
10.1007/s40256-016-0197-9